Novartis gets FDA priority review for malaria drug

15 Sep 2008
ZURICH, Sept 15 (Reuters) - Swiss drug firm Novartis has won priority review from the U.S. Food and Drug Administration for its Coartem anti-malaria drug.

Novartis said in a statement that Coartem, the leading artemisinin-based combination treatment (ACT) for malaria worldwide that is used widely in Africa, could become the first such treatment approved for use in the United States.

(Reporting by Emma Thomasson)